Ocrelizumab

證據等級: L5

預測適應症: 5 個

Ocrelizumab: From Multiple Sclerosis to HER2 Positive Breast Carcinoma

One-Sentence Summary

Ocrelizumab is an anti-CD20 monoclonal antibody; based on the mechanistic notes accompanying this evidence pack, its established use is in multiple sclerosis (B-cell depletion), though this is not confirmed in the formal indication/MOA fields (flagged as a data gap). The TxGNN model predicts possible efficacy in HER2 Positive Breast Carcinoma, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure graph-relation signal with no corroborating mechanistic or clinical evidence.

Quick Overview

Item	Content
Original Indication	Multiple Sclerosis (referenced only in the rationale narrative; not present in the drug's formal `original_indications`/`original_moa` fields — see data gap DG002)
Predicted New Indication	HER2 Positive Breast Carcinoma
TxGNN Prediction Score	99.89%
Evidence Level	L5
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the drug-level field (flagged as data gap DG002, High severity). Based on the rationale notes embedded in this evidence pack, ocrelizumab is an anti-CD20 monoclonal antibody whose known effect is depletion of CD20-positive B cells, with its approved use referenced as multiple sclerosis.

HER2-positive breast carcinoma is driven by overexpression/amplification of the HER2/neu receptor tyrosine kinase — a pathway with no established interaction with CD20+ B-cell depletion. While tumor-infiltrating B cells are present in some breast cancer tissue, there is no evidence that depleting them reverses HER2-driven tumor growth.

The high TxGNN score (99.89%) most likely reflects a graph-topology association within the knowledge graph rather than a biologically interpretable mechanism. The same pattern repeats across all five predicted indications in this pack (HER2+, normal breast-like, PR+, luminal A/B, PR− breast cancer) — all are breast cancer molecular subtypes with no known CD20/B-cell-depletion linkage, and all are rated L5 with a Hold recommendation. Rank 4 does carry 19 attached literature records, but on inspection these are keyword mismatches (B-cell developmental biology, hepatitis B vaccines, HLA-B allele typing) unrelated to either ocrelizumab or breast cancer, and should be treated as noise rather than supporting evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

New Zealand Market Information

Ocrelizumab is not currently marketed in New Zealand (0 authorizations on file); no product license records are available for this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and DDI data are all unavailable in this pack — TFDA/Medsafe package insert data is flagged as a Blocking data gap, DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by TxGNN's graph score (L5) — zero clinical trials, zero relevant literature, and no plausible mechanistic link between CD20+ B-cell depletion and HER2-driven breast cancer. The drug is also not marketed in New Zealand, and core safety data is blocked by a missing package insert.

To proceed, the following is needed:

TFDA/Medsafe package insert (warnings, contraindications) — currently Blocking (DG001)
Confirmed mechanism of action and original approved indication — currently High severity gap (DG002)
Preclinical/mechanistic studies establishing a biological pathway between B-cell depletion and HER2 signaling
Any real-world clinical or case-level evidence in breast cancer populations before advancing past S0
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.